×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.80 (+0.09%)
AAPL   139.23 (+1.30%)
MSFT   260.26 (+1.47%)
META   163.94 (+2.03%)
GOOGL   2,234.03 (-0.27%)
AMZN   108.92 (+1.42%)
TSLA   685.47 (-1.79%)
NVDA   155.42 (-2.75%)
NIO   21.86 (-2.24%)
BABA   116.03 (-0.63%)
AMD   77.99 (-3.45%)
MU   56.02 (-3.18%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.65 (-0.28%)
AMC   13.65 (+2.02%)
PFE   50.94 (+0.55%)
PYPL   71.47 (-0.49%)
NFLX   178.36 (-0.69%)
NYSE:BTX

Brooklyn ImmunoTherapeutics Stock Forecast, Price & News

$0.55
0.00 (0.00%)
(As of 06/29/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.52
$0.57
50-Day Range
$0.48
$1.35
52-Week Range
$0.46
$21.03
Volume
260,463 shs
Average Volume
507,665 shs
Market Capitalization
$31.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
30 days | 90 days | 365 days | Advanced Chart

Receive BTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter.

BTX Stock Forecast (MarketRank)

Overall MarketRank

0.00 out of 5 stars

Medical Sector

1420th out of 1,433 stocks

Biotechnology Industry

6th out of 8 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
Brooklyn ImmunoTherapeutics logo

About Brooklyn ImmunoTherapeutics (NYSE:BTX)

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

BTX Stock News Headlines

Brooklyn ImmunoTherapeutics (NYSE:BTX) Trading Down 0.8%
See More Headlines

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
10
Year Founded
N/A

Company Calendar

Last Earnings
4/15/2022
Today
6/29/2022

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Market Cap
$31.60 million
Optionable
Optionable
Beta
N/A














Brooklyn ImmunoTherapeutics Frequently Asked Questions

How has Brooklyn ImmunoTherapeutics' stock price performed in 2022?

Brooklyn ImmunoTherapeutics' stock was trading at $2.05 on January 1st, 2022. Since then, BTX stock has decreased by 73.2% and is now trading at $0.55.
View the best growth stocks for 2022 here
.

How were Brooklyn ImmunoTherapeutics' earnings last quarter?

Brooklyn ImmunoTherapeutics, Inc. (NYSE:BTX) announced its quarterly earnings data on Friday, April, 15th. The company reported ($0.16) earnings per share (EPS) for the quarter.
View Brooklyn ImmunoTherapeutics' earnings history
.

Who are Brooklyn ImmunoTherapeutics' key executives?

Brooklyn ImmunoTherapeutics' management team includes the following people:
  • Dr. Kevin A. D'Amour Ph.D., Chief Scientific Officer (Age 49, Pay $448.62k)
  • Dr. Roger Sidhu M.D., Chief Medical Officer (Age 46, Pay $501.95k)
  • Dr. Matthew Angel Ph.D., CEO & Director (Age 41)
  • Mr. Andrew C. Jackson, Chief Financial Officer (Age 53)
  • Dr. Monil Shah M.B.A., Pharm.D., Chief Operating Officer
  • Ms. Sandra M. Gurrola, Principal Accounting Officer & VP of Fin. (Age 55)
  • Mr. Jay Sial, Chief Admin. Officer (Age 57)
  • Ms. Lynn Sadowski Mason M.S., Exec. VP of Clinical Operations (Age 43)
  • Ms. Susan McClatchey, VP & Head of Quality

What is Brooklyn ImmunoTherapeutics' stock symbol?

Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "BTX."

How do I buy shares of Brooklyn ImmunoTherapeutics?

Shares of BTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Brooklyn ImmunoTherapeutics' stock price today?

One share of BTX stock can currently be purchased for approximately $0.55.

How much money does Brooklyn ImmunoTherapeutics make?

Brooklyn ImmunoTherapeutics (NYSE:BTX) has a market capitalization of $31.60 million.

How many employees does Brooklyn ImmunoTherapeutics have?

Brooklyn ImmunoTherapeutics employs 10 workers across the globe.

How can I contact Brooklyn ImmunoTherapeutics?

The official website for Brooklyn ImmunoTherapeutics is www.brooklynitx.com. The company can be reached via phone at 212 582 1199.

This page (NYSE:BTX) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.